The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)
Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients
Article Information
vol. 27 no. 7 1647-1653
PubMed
Published By
Print ISSN
Online ISSN
History
- April 5, 2004
- October 5, 2003
- Published in print June 25, 2004.
Copyright & Usage
DIABETES CARE
Author Information
- Bernard Charbonnel, MD1,
- John Dormandy, FRCS(ED), FRCS(ENG), DSC2,
- Erland Erdmann, MD, FESC, FACC3,
- Massimo Massi-Benedetti, MD4,
- Allan Skene, PHD5 and
- PROactive Study Group
- 1Clinique d’Endocrinologie, Nantes Cedex, France
- 2Department of Vascular Surgery, St. George’s Hospital, London, U.K
- 3Klinik III für Innere Medizin, Köln, Germany
- 4Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
- 5Nottingham Clinical Research Limited, Isaac Newton Centre, Nottingham Science and Technology Park, Nottingham, U.K
- Address correspondence and reprint requests to Professor Bernard Charbonnel, MD, PROactive, Clinique d’Endocrinologie, Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France. E-mail: bernard.charbonnel{at}sante.univ-nantes.fr